Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (LLY) is following the right approach for the obesity drugs business as it explores multiple ways to address the balance between demand and supply, according to Truist Securities. The ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products.Novo Nordisk markets its semaglutide drugs as Ozempic pre ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months. News. ... Lilly is already a leader in the obesity market, ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald ...

Eli Lilly and Co. gained more oomph in its weight-loss battle with Novo Nordisk A/S, as the firm highlighted another batch of results from Surmount-5, a phase IIIb open-label trial evaluating the ...